Abstract Disorders of sex development (DSD) include a wide range of anomalies among the chromosomal, gonadal, and phenotypic (genital) characteristics that define sexual differentiation. At present, a definition as Different sexual development (DSD) is currently preferred. They originate in the pre-natal stage and are classified according to the sex chromosomes present in the karyotype. The known genetic causes are numerous and heterogeneous, ଝ Please cite this article as: Guerrero-Fernández J, Azcona San Julián C, Barreiro Conde J, Bermúdez de la Vega JA, Carcavilla Urquí A, Castaño González LA, et al. Guía de actuación en las anomalías de la diferenciación sexual (ADS)/desarrollo sexual diferente (DSD 
Introduction
Disorders of sex development is a term that encompasses a broad spectrum of conditions with atypical development of the chromosomal, gonadal and phenotypic (genital) characteristics that define sexual differentiation. 1 The 2006 Chicago Consensus Statement 1,2 referred to these conditions as ''disorders or abnormalities of sex development'', although it still also used the term ''intersex'' ( Table 1) . The growing awareness of the disapproval elicited by this new medical terminology has led to a progressive reconsideration of the terms, and the term currently proposed to refer to these conditions is ''differences of sex development'' (DSD). 3 Sexual differentiation during prenatal development involves a series of processes whose initiation and regulation involve numerous genes, proteins and hormones. The first stage in gonadal and genital development is shared by both sexes and spans the first 6 weeks following conception, an interval during which the embryo is pluripotent. Gonadal differentiation starts in the 7th week and is regulated by a multitude of genes, with the SRY gene in the Y chromosome playing a key role in the development of the testes. Genital differentiation (internal and external) is regulated by the effects of hormones synthesised by the testes in male embryos, or by their absence in female embryos. Any abnormality of genetic or environmental origin that impacts these processes at any level may result in inadequate development of the gonads (gonadal dysgenesis), the internal genitalia (absence or abnormal features) and/or the external genitalia (insufficient or excessive virilization). These abnormalities may be apparent at birth, manifesting as genital ambiguity or discordance between genotypic and phenotypic sex, during puberty, manifesting as delayed puberty, amenorrhoea or insufficient or excessive virilization, or later in life, manifesting as infertility or early menopause, and it is important to remember that they can be associated to anomalies in other systems or be life-threatening if they are associated with adrenal insufficiency. The approach to their management is also critical in infants when it comes to gender assignment. For all the above reasons, these conditions always require medical and psychosocial care delivered by a multidisciplinary team.
With the exception of hypospadias as an isolated genital malformation, the nonclassic form of congenital adrenal hyperplasia (CAH) and sex chromosome disorders, their incidence is less than 1/2000 individuals, so they are considered ''rare diseases''. The recommended approach to the diagnosis of any suspected DSD now follows, although some of the diagnostic tests are used exclusively in the assessment of newborns with genital ambiguity. As noted above, the diagnosis should be made by a multidisciplinary team.
History taking and physical examination

Personal history
• Parental consanguinity.
• Potential prenatal exposure to androgens, androgen antagonists or other drugs.
• Maternal virilization during pregnancy.
Family history
Family history of hypospadias, infertility, amenorrhoea or early menopause, salt-losing or unexplained infant deaths.
Physical examination
A careful inspection with palpation of the genitalia must be performed:
• Assess the degree of virilization/masculinisation: there are two scales that can be used interchangeably.
---In female individuals (XX), although it can also be useful in general for any other chromosome pair or when the results of karyotyping are not yet available, the Prader staging system, which can be found in p. 9 of the document Guía de actuación en las anomalías de la diferenciación sexual (ADS)/desarrollo sexual diferente (DSD) 4 (''Guideline for the management of disorders/differences of sex development (DSD)''), to which we will refer to from hereon as the DSD Guideline.
---In male individuals (XY), by means of the external masculinisation score (p. 10 of the DSD Guideline). 4 • Palpation of the gonads along the inguinal canal (from the labioscrotal fold to the abdomen).
• Assessment of hydration and blood pressure. In cases with persistent jaundice accompanied by recurrent episodes of hypoglycaemia, the possibility of hypopituitarism with growth hormone and cortisol deficiency in addition to gonadotropin deficiency should be considered.
• Rule out additional dysmorphic features, as genital malformations may occur in the context of multiple malformation syndromes.
First-line diagnostic tests
There are three fundamental tests:
Karyotype analysis (peripheral blood) Essential during the diagnostic evaluation, as it helps place the patient in one of the 3 main categories of the DSD classification (Table 1) . It can be supplemented with FISH analysis using probes specific for the Y (SRY) and X (DX 1 ) chromosomes.
Hormone evaluation from 48 h post birth 5 • 17-Hydroxyprogesterone. It can be used to screen for CAH secondary to 21-hydroxylase deficiency, which is the most common cause of 46,XX DSD. Its levels must be measured in all newborns with bilateral cryptorchidism or with genital ambiguity.
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• Dehydroepiandrosterone (DHEA), progesterone and, if possible, 17-hydroxypregnenolone and 11-deoxycortisol. They allow the diagnosis of less common forms of CAH and various inherited metabolic disorders.
• Testosterone, follicle-stimulating hormone (FSH) and luteinising hormone (LH). Measurement of the basal serum levels of testosterone and its precursors in patients with 46,XY DSD is useful in the first year of life, performing tests within 36 h of birth and during mini-puberty, between days 15 and 90 post birth (a window that can be expanded to 6 months of age, during the descent in testosterone levels). The levels of LH and FSH should also be measured in the sample obtained for the second test.
• Basal cortisol and adrenocorticotropic hormone (ACTH).
Essential for diagnosis of panhypopituitarism and enzymatic disorders that affect adrenal steroidogenesis.
• Anti-Müllerian hormone (AMH) and inhibin B. Measurement of serum levels of AMH and/or inhibin B is used to assess Sertoli cell function. 7, 8 • Urinary steroid profile: the ratio of the measured urine concentrations of precursor metabolites and the steroid products of the enzyme with the potential defect may be a more specific and sensitive method to detect the defect compared to measurement of levels in blood.
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Abdominal ultrasound
It is important to assess for the presence of the gonads, uterus and/or vagina. The identification of these structures, especially of the gonads, is not always easy, and therefore lack of detection does not necessarily entail their absence.
Second-line diagnostic tests
These are used when the aetiology remains unclear, or further assessment is desired in cases of suspected DSD:
• Beta-human chorionic gonadotropin (␤-hCG) simulation test (short duration): for assessment of testicular function based on the response of Leydig cells, measuring the levels of synthesised testosterone and its precursors and metabolites, such as dihydrotestosterone. 7, 10 • Indications, protocol and interpretation detailed in pp. 13---14 of the DSD Guideline. 4 • ACTH test:
• Indications and protocol detailed in p 14 of the DSD Guideline. Tables 1 ---4 can be used to follow this approach to diagnosis.
The different molecular studies are used to assess for a variety of genetic disorders:
---Detection of pathogenic changes in the sequence of a gene: the classic Sanger sequencing technique is used when there is a clear candidate gene (for instance, CYP21A2 in case of suspected 21-hydroxylase deficiency or AR in case of androgen insensitivity). However, due to the large number of candidate genes that may be involved in DSDs, many laboratories use next generation sequencing (NGS) techniques that allow the simultaneous sequencing of a variable number of genes; these methods can be used to find the genetic cause quicker and at lower cost. ---Detection of copy-number variations: some DSDs are due to variations in the number of copies of certain genes (increased number of copies or deletions of alleles or chromosome loci). They are detected by methods such as multiple ligation-dependent probe amplification (MLPA) or microarray-based comparative genomic hybridisation (aCGH).
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---Lastly, whole exome sequencing (WES) or whole genome sequencing will be performed if there is no clear candidate gene, the results obtained with gene panels are normal, or in the context of studies seeking to identify novel candidate genes. These methods provide substantial amounts of information and must be used in the framework of strict technical and ethical protocols, with participation of the multidisciplinary team that will contribute to the interpretation of results.
Conditions that present with genital ambiguity or discordances between genetic, gonadal and phenotypic sex development. Differential diagnosis Tables 2 ---4 summarise the different types of DSDs classified according to karyotype, phenotype, internal and external genitalia, biochemical abnormalities and the recommended approach to diagnosis.
Management Gender assignment
Gender assignment is a complex and critical decision in the management of DSDs. The decision rests with the parents, counselled by a multidisciplinary team (paediatric endocrinologists, surgeons, paediatric urologists, gynaecologists, neonatologists, geneticists, psychologists, social workers etc.). It is essential that this process be managed in reference centres with teams experienced in the management of DSDs, taking into account, among others, cultural and religious factors in different populations and the impact of the decision on the adult life of affected individuals (gender dysphoria, gonadectomy, dissatisfaction with the appearance of genitalia, etc.). Historically, the approach consisted of early surgery with the aim of achieving cosmetically normal external genitalia and excising the gonads to match the assigned gender. However, in recent years elective surgery has been deferred to allow the patient to participate in decision-making in regard to both gender assignment and surgical intervention. In cases where it is possible to defer surgery for DSD and where families wish to take this approach, it is essential to establish a non-surgical care plan to help parents and patients cope with the social pressure associated with a child having atypical genitalia.
The current criteria for gender assignment are based on (1) psychosexual outcomes in adults with an aetiological diagnosis, (2) the potential for fertility, (3) surgical options and (4) the need for hormone replacement therapy during puberty. 
Medical treatment
Cases that present with adrenal insufficiency (glucocorticoids and/or mineralocorticoids) require immediate initiation of replacement therapy with administration of hydrocortisone. 6 When it comes to sex steroid replacement for induction of puberty, there is no widespread agreement as to the time it should be initiated, the initial dose or the rate at which the dose should be increased. Most research groups emphasise the need to initiate pharmacologic treatment at low doses that are then progressive increased, but they disagree on the age at which it should start and the dosage in the first years of treatment. Generally, it is agreed that puberty should be induced when girls reach an approximate bone age of 11 years and boys a bone age of 12 years, increasing the dose at a slow pace. The DSD Guideline 4 presents the most widely approved approach to sex steroid replacement therapy during puberty in pp. 35 and 37 (Tables 6 and 7 of the guideline). It also provides detailed recommendations for treatment in regards to (1) testosterone treatment in prepubertal boys to promote penile growth; (2) Klinefelter syndrome; (3) Turner syndrome; (4) complete androgen insensitivity syndrome (CAIS); (5) partial androgen insensitivity syndrome (PAIS); (6) 5␣-reductase deficiency; (7) 17␤-hydroxysteroid dehydrogenase deficiency; (8) 46,XX gonadal dysgenesis; (9) 46,XY complete gonadal dysgenesis; (10) 46,XY partial gonadal dysgenesis, and (11) persistent Müllerian duct syndrome.
Surgical treatment
Surgical treatment of DSDs frequently involves irreversible changes to the patient's phenotype. 1 The decision to choose this approach must be made jointly by the family and the multidisciplinary team advising the family. Where possible, the patient should be involved in the decision-making process. For this reason, in recent years there has been a growing tendency to defer surgery until the patient is of an age where they can become involved. 25, 26 In cases where surgery is performed at early ages, mutilating and irreversible procedures should be avoided.
Last of all, there is unanimous agreement that these procedures should only be performed by specialised surgeons in hospitals with considerable experience in the field.
The DSD Guideline 4 specifies the different types of surgical intervention that can be performed for treatment of DSD by age and gender, including genital tubercle surgery (pp. The decision whether to perform prophylactic gonadectomy is complex. It must be made on a case-by-case basis taking into account its potential risks and benefits as well as: (1) the assigned gender, if different from gonadal sex; (2) the risk of malignant transformation, and (3) gonadal function (hormonal function and potential fertility). 27 The DSD Guideline details the risk of malignant transformation based on the DSD classification (pp. 43---47). 4 There is no widespread consensus when it comes to gonadectomy, although it is agreed that it should be considered in cases of gonadal dysgenesis or dysplasia, especially when the location of the gonads is intraabdominal.
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Transition to adult care
The need to guarantee a seamless transition from paediatric to adult care has been highlighted in several paediatric specialties, and patients with DSDs are particularly vulnerable at this juncture. 29 There are published guidelines for the transition of patients with specific DSDs, such as Turner syndrome, 30, 31 Klinefelter syndrome 32, 33 or CAH. 34, 35 • Some of the general aspects of the transition to adult care in patients with DSDs are: • Genital examination: in women with DSDs, a vaginal examination should be considered at some point during the followup. Women do not always require lengthening of the vagina, and should receive guidance in contemplating whether they wish to have sexual intercourse with penetration and when to start engaging in sexual relations. If assigned the male gender, they require masculinising genitoplasty and androgen therapy to achieve a male appearance. 1. 23% (9/54) are dissatisfied with the assigned gender, with a similar proportion of gender dysphoria in patients assigned to either gender 15 ; except in cases of 5␣R and 17␤-HSD-3 deficiency, in which male gender assignment is recommended. 2. There are few long-term studies on gender dysphoria in these patients. 3 . In most individuals, fertility is unlikely, regardless of the assigned gender. In individuals with PAIS, fertility is possible if the testes are not resected. 16 Fertility is also possible in individuals with partial gonadal dysgenesis (PGD) with implantation of a fertilised donor egg if the uterus is sufficiently developed; it must be taken into account that there is an intermediate risk of developing germ cell tumours if the testes are preserved.
• Gonadectomy and risk of malignant transformation: in patients with DSDs at risk of malignant transformation of the gonads, the patient must be informed of this risk and be followed up in adult care.
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• Psychological problems: several studies have evinced the overwhelming need for psychological support of patients with DSDs during adolescence, most likely extending into adulthood.
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• Information about the diagnosis: patients will most likely receive detailed information about their condition when the time to transition to adult care nears. 39 Information on the prognosis must include a discussion of potential fertility and the possibility of having offspring through the use of different assisted reproductive technologies. A better understanding of their condition will allow adolescents or young adults to seek support groups or additional support through social networks.
The proposed protocol for transition to adult care in patients with DSDs can be found in pp. 51 and 52 of the DSD Guideline. 4 
Registers
Multidisciplinary teams are unable to establish the aetiology of DSDs in 40% to 50% of cases, especially in patients with a 46,XY karyotype. Considering the diversity and complexity of DSDs and the need to investigate further unknown causes, health professionals need to share their knowledge, or, in other words, record information in registers. 40 In Spain, there are two DSD registers that are currently active and accessible. One is a Spanish register, and the other an international one:
• The Spanish Register of DSDs-CAH is integrated in the Register of Rare Diseases of the Instituto de Salud Carlos III (ISCIII) in Madrid (https://registroraras.isciii.es).
• The International DSD Registry (I-DSD Registry, https://www.i-dsd.org/).
Peer support groups and advocacy organisations
In Spain, there are two patient associations affiliated to the Federación Española de Enfermedades Raras (Spanish Federation of Rare Diseases, FEDER) that include individuals affected by some type of DSD:
• 
Structure of care in Spain and Europe
There are two working groups devoted to DSDs in the Sociedad Española de Endocrinología Pediátrica (Spanish Society of Paediatric Endocrinology, SEEP): one on CAH, and one on the rest of DSDs (the working group that authored this guideline). The Sociedad de Endocrinología y Nutrición (Spanish SEEN) has a working group devoted to gender identity (GIDSEEN) that also investigates DSDs, although its main focus is transsexuality. In Spain, the Ministry of Health, Social Services and Equality is considering the need to establish a system for the accreditation of reference centres, departments and units devoted to endocrinological diseases. The two Spanish endocrinological societies (SEEP and SEEN) and the Asociación Española de Pediatría (Spanish Association of Paediatrics, AEP) have presented an initial set of files corresponding to several diseases, including one for DSDs (2017).
Since 2017, European Reference Networks for Rare Diseases (ERN) have been established in Europe. One is the Rare Endocrine Diseases Reference Network (EndoERN), which
